Table 1 Patient baseline characteristics
Patient baseline characteristics | ||||
|---|---|---|---|---|
All | ||||
pts | % | |||
histology | mucoepidermoid carcinoma | 18 | 45 | |
adeno carcinoma | 8 | 20 | ||
acinic cell carcinoma | 3 | 8 | ||
squamous cell carcinoma | 2 | 5 | ||
salivary duct carcinoma | 2 | 5 | ||
NOS | 2 | 5 | ||
basal cell-adeno carcinoma | 2 | 5 | ||
adenosquamous carcinoma | 1 | 3 | ||
myoepithelial carcinoma | 1 | 3 | ||
basaloid carcinoma | 1 | 3 | ||
stage | T 1 | 3 | 8 | |
T 2 | 5 | 13 | ||
T 3 | 13 | 33 | ||
T 4a | 10 | 25 | ||
T 4b | 7 | 18 | ||
T 4c | 1 | 3 | ||
unknown | 1 | 3 | ||
N+ | 16 | 40 | ||
M1 | 3 | 8 | ||
treatment for recurrent disease | 7 | 18 | ||
site | parotid gland | 20 | 50 | |
submandibular gland | 5 | 13 | ||
oropharynx | 3 | 8 | ||
maxilla | 2 | 5 | ||
palate | 2 | 5 | ||
lacrimal gland | 2 | 5 | ||
paranasal sinus | 2 | 5 | ||
petrous bone | 2 | 5 | ||
middle ear | 1 | 3 | ||
nasopharynx | 1 | 3 | ||
age | median in years [range] | 60 | 35-80 | |
follow-up | all, median in months [range] | 25.5 | 2.5-58.4 | |
alive, median in months [range] | 27.3 | 3-58.4 | ||
target volume | CTV1 (boost) in ml | 120 | 34-564 | |
CTV2 (extended target volume) in ml | 424 | 105-1538 | ||
dose | C12 in GyE [range] | 23.95 | 17.4-24.4 | 2 pts: C12 only with 66 GyE |
IMRT in Gy [range] | 50 | 42-56.4 | ||
total in GyE [range] | 74 | 50.4-74.8 | ||